Medical & Analytical Review Policy

What We Review

PharmaBenefits.ai is a B2B employer pharmacy benefits intelligence platform. Our content informs decisions about PBM contracts, formulary design, and plan economics rather than individual clinical care. Our review process therefore focuses on analytical accuracy, source integrity, and methodological rigor rather than bedside clinical review.

Who Reviews Our Analysis

Before publication, substantive analytical content is reviewed for:

• Source accuracy: every benchmark, PEPM figure, GDR number, or PBM market statistic is traced to CMS NADAC, FTC reports, Drug Channels Institute, SEC filings, or other named primary sources.
• Methodology: spread, rebate, and total-cost calculations follow consistent formulas that we disclose in the Sources page.
• Currency: pricing data reflects the most recent CMS NADAC publication at the time of review; regulatory references are checked against the current Inflation Reduction Act provisions and CMS Transparency in Coverage rules.
• Editorial voice: content is written by or reviewed by analysts with direct experience in employer benefits consulting, pharmacy benefit design, and PBM contract negotiation.

What We Don't Do

PharmaBenefits.ai does not provide clinical advice, drug selection recommendations for individual patients, or legal/ERISA compliance opinions. When a decision requires a licensed professional, we say so and point readers to pharmacy benefits consultants, ERISA attorneys, actuaries, or stop-loss brokers.

Corrections

If you identify an error in our data or analysis, please contact the editorial team. We correct substantive errors promptly and note material updates at the bottom of affected articles.

Last updated: April 2026